Brain tumor device combo study pulled before it started
NCT ID NCT04129515
First seen Jan 06, 2026 · Last updated May 03, 2026 · Updated 16 times
Summary
This study was designed to test a device (NovoTTF-200A) combined with the immunotherapy drug pembrolizumab in people with melanoma that had spread to the brain. The goal was to see if the combination was safe and effective. However, the study was withdrawn before enrolling any participants, so no results are available.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC MELANOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Lifespan Cancer Institute
Providence, Rhode Island, 02903, United States
Conditions
Explore the condition pages connected to this study.